ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behçet’s Syndrome"

  • Abstract Number: 1556 • ACR Convergence 2023

    Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

    Sinem Nihal Esatoglu1, Sabriye Guner1, Sevim Guler2, Gulen Hatemi1, Nuray Kepil3, Yusuf Ziya Erzin4, Aykut Ferhat Celik4 and Ibrahim Hatemi4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

    Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
  • Abstract Number: 1557 • ACR Convergence 2023

    De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

    Sinem Nihal Esatoglu1, Ozge Sonmez2, Didar Ucar3, Elif Kaymaz4, Yesim Ozguler5, Serdal Ugurlu6, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko7, Vedat Hamuryudan1, Ugur Uygunoglu8, Zekayi Kutlubay9 and Gulen Hatemi1, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Istanbul, Turkey, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 8Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…
  • Abstract Number: 1558 • ACR Convergence 2023

    Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

    Didar Ucar1, Basak Ecem Bircan2, Nigar Rustamli2, Bilge Batu Oto1, Vedat Hamuryudan3, Sinem Nihal Esatoglu3 and Gulen Hatemi3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • Abstract Number: 1560 • ACR Convergence 2023

    Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China

    Jiachen Li1, Feng Sun2, Wenyan Zhou1 and Tian Liu1, 1Peking University People's Hospital, Beijing, China, 2Peking University People’s Hospital, Beijing, China

    Background/Purpose: Behcet's syndrome (BS) is an autoimmune disease characterized by recurrent mucocutaneous ulcerations, vascular and nervous system involvement. While there have been a lot of…
  • Abstract Number: 0044 • ACR Convergence 2023

    Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis

    Menghao Zhang1, Na Kang2, Xin Yu1, Wanli Liu2 and Wenjie Zheng1, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 2Beijing Key Lab for Immunological Research on Chronic Diseases, School of Life Sciences, Institute for Immunology, Tsinghua University, Beijing, China

    Background/Purpose: Behçet’s disease (BD) is a chronic vasculitis characterized by polymorphonuclear neutrophils (PMNs) hyperactivation with unknown etiology. The over-productions of neutrophil extracellular traps (NETs) and…
  • Abstract Number: 1561 • ACR Convergence 2023

    Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study

    Koichi Sugihara1, Risa Wakiya2, Yusuke Ushio3, Shusaku Nakashima2, Hiromi Shimada2, Taichi Miyagi4, Kanako Chujo5, Ryoko Kagawa3, Hayamasa Yamaguchi3, Tomohiro Kameda2 and Hiroaki Dobashi6, 1Kagawa University, Miki-cho, Kita-gun, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 5Kagawa University, Miki, Kita District, Kagawa, Japan, 6Kagawa University, Kagawa, Japan

    Background/Purpose: Arthritis is positioned as one of the main symptoms in Behcet's disease (BD), and it is a relatively frequent symptom that is observed in…
  • Abstract Number: 0215 • ACR Convergence 2023

    Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort

    Erika Biegelmeyer1, Mariana Freitas de Aguiar1, Priscila Dias Cardoso Ribeiro1, Ketty Lysie Libardi Lira Machado2, Maria da Penha Gomes Gouveia2, Camila Maria Paiva França Telles3, Samuel Elias Basualto Dias3, Natália Sarzi Sartori4, Thaís Evelyn Karnopp5, Vanessa de Oliveira Magalhães1, Flávia Maria Matos Melo Campos Peixoto1, Laiza Hombre Dias2, Débora Marques Veghini2, Rodrigo Vieira de Rezende6, Katia Lino Baptista6, Ana Karla Guedes de Melo7, Vitor Alves Cruz8, Maria Cecília Dias Corrêa9, Adriana Maria Kakehasi10, Rejane Maria Rodrigues de Abreu Vieira11, Valderilio Feijó Azevedo12, Olindo Assis Martins-Filho13, Charlles Heldan de Moura Castro1, Ricardo Xavier14, Andréa Teixeira-Carvalho13, Viviane Angelina de Souza9, Odirlei André Monticelo15, Marcelo Pinheiro16, Edgard Torres dos Reis Neto1, Emilia Sato1, Gilda Ferreira17, Gecilmara Pileggi18, Valeria Valim19 and Alexandre wagner Silva de Souza20, 1Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, 3Universidade Federal do Amazonas, Manaus, Brazil, 4Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 6Universidade Federal Fluminense, Niterói, Brazil, 7Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, 8Universidade Federal de Goiás, Goiânia, Brazil, 9Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, 10Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 11Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, 12Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, 13Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, 14Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 15Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 16UNIFESP/ EPM, São Paulo, Brazil, 17Federal University of Minas Gerais, Belo Horizonte, Brazil, 18UNIFESP, Ribeirão Preto, Brazil, 19Universidade Federal do Espírito Santo, Vitória, Brazil, 20Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
  • Abstract Number: 1562 • ACR Convergence 2023

    Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population

    Sundus Mian1, Talia Meisel2, Hussain Md1, Xianhong Xie3, Tamara Tanner1, Anand Kumthekar4 and Bibi Ayesha4, 1Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

    Background/Purpose: Behcet's disease (BD) is a vasculitis with both thrombotic and bleeding complications which can make management challenging. Thrombosis is due to direct vascular inflammation,…
  • Abstract Number: 0258 • ACR Convergence 2023

    Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation

    Patricia Aires1, Daniela Pioto1, Maria Teresa TErreri2 and Sandro Perazzio3, 1Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil

    Background/Purpose: A20, encoded by TNFAIP3, plays a critical role in NF-κB pathway regulation. A20 haploinsufficiency is a monogenic disorder form of Behçet's disease with a…
  • Abstract Number: 1563 • ACR Convergence 2023

    Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease

    Miriam Retuerto-Guerrero1, Elvira Díez Álvarez1, Javier Narvaez2, Rosa Fornons Servent3, Carlos Moreno Vilchez3, Jenaro Graña Gil4, Uxía Couto Lareo5, Carmen San José-Méndez4 and Clara Moriano Morales1, 1Rheumatology, Hospital Universitario de León, León, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Dermatology, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain, 4Rheumatology, Hospital A Coruña, A Coruña, Spain, 5Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain

    Background/Purpose: Behçet's disease (BD) is characterized by great clinical heterogeneity. The therapeutic strategy for BD could be tailored to the specific needs of the patient,…
  • Abstract Number: 0692 • ACR Convergence 2023

    Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

    Johannes Nowatzky1, Ziyan Lin2, Yesim Ozguler3, Alireza Khodadadi-Jamayran2, Didar Ucar4, Aristotelis Tsirigos5, Gulen Hatemi6 and Olivier Manches7, 1NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, 2NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, 3NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 5NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France

    Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
  • Abstract Number: 1564 • ACR Convergence 2023

    Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease

    fatma Alibaz-Öner1, Rabia Ergelen2, Seda Kutluğ Ağaçkıran3, Fatma Temiz4, Tulin Ergun5 and Haner Direskeneli6, 1Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Marmara University, School of Medicine, Department of Radiology, Istanbul, Turkey, 3Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, 4Marmara University, School of Medicine, Department of Internal Medicine, Istanbul, Turkey, 5Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, 6Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey

    Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on multi-systemic clinical manifestations after ruling out other potential causes. There is no specific diagnostic…
  • Abstract Number: 0701 • ACR Convergence 2023

    Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Jose Luis Martin-Varillas3, Carmen Alvarez Reguera1, Lara Sanchez-Bilbao4, David Martinez-Lopez5, Raul Fernandez1, Ivan Ferraz Amaro6, Jose Luis Hernandez1 and Ricardo Blanco7, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Spain, 5Hospital de Sierrallana, Santander, Spain, 6Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 7Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
  • Abstract Number: 2517 • ACR Convergence 2023

    The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

    Erdem Bektas1, Rabia Deniz2, Zeliha Emrence3, Sema Sırma Ekmekci3, Neslihan Abacı3, Shirkhan Amikishiyev4, Yasemin Yalçınkaya4, Bahar Artim Esen4, Murat Inanç5 and Ahmet Gul6, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 2University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, 3Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology